Drugs / ERAS-4001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07021898 | Aug 2025 → Aug 2028 expected | metastatic neoplasm | Erasca, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERAS-4001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07021898 ↗ |
| Route | Oral | “ERAS-4001 Administered orally” NCT07021898 ↗ |